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ABSTRACT
PLAGL1/ZAC1 undergoes parental genomic imprint-
ing, is paternally expressed, and is a member of the
imprinted gene network (IGN). It encodes a zinc fin-
ger transcription factor with anti-proliferative activity
and is a candidate tumor suppressor gene on 6q24
whose expression is frequently lost in various neo-
plasms. Conversely, gain of PLAGL1 function is re-
sponsible for transient neonatal diabetes mellitus, a
rare genetic disease that results from defective pan-
creas development. In the present work, we showed
that Plagl1 up-regulation was not associated with
DNA damage-induced cell cycle arrest. It was rather
associated with physiological cell cycle exit that oc-
curred with contact inhibition, growth factor with-
drawal, or cell differentiation. To gain insights into
Plagl1 mechanism of action, we identified Plagl1 tar-
get genes by combining chromatin immunoprecipita-
tion and genome-wide transcriptomics in transfected
cell lines. Plagl1-elicited gene regulation correlated
with multiple binding to the proximal promoter region
through a GC-rich motif. Plagl1 target genes included
numerous genes involved in signaling, cell adhesion,
and extracellular matrix composition, including col-
lagens. Plagl1 targets also included 22% of the 409
genes that make up the IGN. Altogether, this work
identified Plagl1 as a transcription factor that coor-
dinated the regulation of a subset of IGN genes and
controlled extracellular matrix composition.
INTRODUCTION
Parental genomic imprinting is an epigenetic mechanism
that was selected at the prototherian to metatherian
transition during mammalian evolution (1–3). It results
in mono-allelic, parent-of-origin-dependent expression of
∼150 genes in eutherian mammals. Although imprinted
genes (IGs) appear to be mostly functionally unrelated,
we recently showed that they are frequently co-regulated
and modulate cell cycle withdrawal when cells enter qui-
escence or differentiate. This observation supports the hy-
pothesis that IGs belong to a single gene network and that
parental genomic imprinting targeted a distinct biological
process (4). We also showed that the imprinted gene net-
work (IGN) comprises non-imprinted genes, including a
significant number of genes controlling the composition of
the extracellular matrix (ECM). These observations raised
several mechanistic questions, in particular with respect to
themechanisms that ensure the co-expression of IGNmem-
bers. The majority of IGs is clustered at a limited number
of loci, which are generally well conserved across euthe-
rian genomes. This clustered organization suggests that IGs
share regulatory elements, which may explain how IG ex-
pression is concerted within a given imprinted locus. How-
ever, at least 20 imprinted loci exist in eutherian genomes,
some IGs are isolated, and non-imprinted IGN genes are
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mostly located outside imprinted loci; hence, additional
mechanisms likely exist to coordinate IGN gene expression.
Zac1/Lot1/Plagl1 was originally identified as a gene
encoding a zinc finger transcription factor with anti-
proliferative activity (5) whose expression was lost upon cell
transformation (6). The human orthologue is a candidate
tumor suppressor gene on 6q24 whose expression is lost
in mammary (7,8) and ovary tumors (9), and other types
of neoplasm (10–12). Inversely, gain of PLAGL1 function
is responsible for transient neonatal diabetes mellitus (13–
15). The molecular mechanisms that underlie Plagl1 activ-
ity are not fully understood at the moment; the biological
context that calls for Plagl1 activity is also unclear. We pre-
viously showed that Plagl1 is a member of the IGN and
regulates the Igf2-H19 locus by direct binding to the en-
hancers located 3′ of H19 (4,16). We also showed that al-
teration of Plagl1 expression resulted in the modulation of
the expression of other IGs, but the underlying mechanism
was unclear. The relationship between Plagl1 activity and
the expression of other IGN members was not known. In
the present work, we identified Plagl1 target genes genome-
wide and showed that Plagl1 regulated a subset of the IGN
genes and ECM genes.
MATERIALS AND METHODS
Mouse tissues
All animal procedures were conducted according to the
guidelines approved by the Institutional Animal Care and
Use Committee. Different tissues were dissected out from
C57BL/6Jmouse E18.5 embryos and neonates and homog-
enized in RNA NOW (Ozyme, Saint Quentin en Yvelines).
To study muscle regeneration, 10 l of a 50 g/ml notexin
solution in 0.9%NaCl or saline alone were injected into the
left tibialis anterior of adult male C57BL/6J mice (79.4 ±
5.0 days). Twomicewere killed before injection and at 6 time
points after injection in each condition. The injected tib-
ialis anteriorwas removed and homogenized in RNANOW.
Saline-injected muscles were used to monitor the absence of
significant gene regulation in the absence of notexin, not to
normalize data.
Cell culture
Neuro-2a cells were grown in high-glucose DMEM supple-
mented with 10% fetal bovine serum and 1% penicillin–
streptomycin in a humidified atmosphere containing 5%
CO2 at 37◦C. AtT20 cells were grown in OptiMEM sup-
plemented with 15% fetal bovine serum and 1% penicillin-
streptomycin. For UV-C irradiation, cells were washed
with PBS 1×, irradiated at 50 J/m2, and refed with cul-
ture medium. Mouse embryonic fibroblasts from wild-
type and Plagl1+/-pat. C57BL/6J mice were prepared us-
ing standard protocols (17) and grown in high-glucose
DMEM supplemented with 10% fetal bovine serum and
1% penicillin–streptomycin. Min6 cells were grown in low-
glucoseDMEM supplemented with 15% fetal bovine serum
and 50 mM -Mercapto-ethanol. E14Tg2a (E14) mouse
embryonic stem cells were maintained and differentiated to
generate cortical cells in vitro as previously described (18).
Transfection
Plasmids encoding -galactosidase, chloramphenicol
acetyl-transferase (CAT), Plagl1/Zac1, CD2 and eGFP
were described previously (4,5,8). 0.8–1 × 106 Neuro-2a
cells were plated one day before transfection in 60-mm
plates and transfected at 80% confluence with 30 l of
Lipofectamine 2000 (Thermo Fisher Scientific) and 10
g of plasmid DNA including 4 g of pRK5-mZac1 or
pRK5-CAT as a control and 6 g of carrier plasmid,
according to the manufacturer’s instructions. We quantified
CAT and Plagl1 levels using RT-qPCR. The expression
levels of CAT, respectively Plagl1, normalized to Tbp, Gus
and Mrpl32 was 24.5 ± 5.4, respectively 12.5 ± 6.0. 3–4
× 106 Min6 cells were plated as above and transfected
with 10 l Lipofectamine 2000 and 5 g of plasmid DNA
including 2 g of pRK5-mZac1 or pRK5-NLSeGFP as a
control and 3 g of carrier plasmid. The expression levels
of eGFP, respectively Plagl1, normalized to Tbp, Gus and
Mrpl32 was 789.4 ± 323.5, respectively 273.1 ± 91.0.
Immunological techniques
Western blots were performed on total cell lysates (40 g
total protein) using anti-Zac1 antibody (5) (1:4000) and
anti-actin (Merck Cat. No. MAB1501; 1:2000). Anti-rabbit
and anti-mouse secondary antibodies were from Cell Sig-
naling (Cat. No. 7074) and Thermo Fisher Scientific (Cat.
No. 32430), respectively. For immunofluorescence experi-
ments, anti-Th antibody (Merck Cat. No. MAB318; 1:200)
and anti-Zac1 antibody (1:4000) were incubated overnight
at 4◦C and secondary antibody (Thermo Fisher Scientific
Cat. No. A11010, 1:500) for 45 min at room tempera-
ture. Nuclei were stained with DAPI (1 g/ml). Coverslips
were mounted withMowiol and examined with an Axioim-
agerZ1 fluorescence microscope (Zeiss).
Cell cycle analysis
Neuro-2a cells were transfected as above with 1 g of
pRK5-CD2 together with 4 g of pRK5-mZac1 or pRK5-
CAT as a control and 5 g of carrier plasmid. We selected
CAT as a control for the cell cycle experiments because,
among the three genes that we tested, i.e. CAT, GFP and
-galactosidase, CAT was the most neutral with respect
to cell proliferation compared to untransfected Neuro-2a
cells (data not shown). Thirty hours later, cells were pre-
pared and stained with 0.5 g FITC-conjugated anti-CD2
antibody and 50 g/ml propidium iodide as previously de-
scribed (7). Propidium iodide and FITC fluorescence in-
tensities were determined using a FACScan flow cytome-
ter (Becton–Dickinson) and the cell cycle distribution of
the 10%most CD2-positive cells was analyzed usingModfit
software (Verity Software House).
Promoter activity measurement
Nptx1 andMpl promoters were PCR amplified frommouse
genomic DNA with appropriate primers (Supplementary
Table S1) and cloned upstream of the Luciferase/SV40
polyadenylation cassette in pGL3 (Promega). The genomic
coordinates (mm9) were chr11(–): 119,409,017–119,409,960
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for Nptx1 0.9kb and chr11(–): 119,409,017–119,410,530
for Nptx1 1.5kb constructs, and chr4(–): 118,130,034–
118,131,876 for Mpl 1.8kb and chr4(–): 118,130,034–
118,130,876 for Mpl 0.8kb constructs. The CMV-based
pRK7-gal plasmid was used to normalize for transfection
efficiency. Plasmids were transfected into Neuro-2a cells
and Luciferase and -galactosidase activities were mea-
sured 24 hours later as previously described (15).
Digital gene expression
Sixteen hours after transfection, total RNA was extracted
using the RNAqueous kit (Thermo Fisher Scientific, Cat.
No. AM1912) and treated with DNase I (DNA-free,
Thermo Fisher Scientific) according to the manufacturer’s
instructions. Libraries were prepared from two biological
replicates of each condition (Plagl1- and CAT-transfected
Neuro-2a) using the Digital Gene Expression-Tag Profiling
Kit with DpnII (Illumina, Cat. No. FC-102-1007) accord-
ing to the manufacturer’s instruction. Briefly, 2 g of total
RNA were incubated with magnetic oligo(dT) beads to se-
lect poly(A)+ RNA. Reverse transcription was performed
on capturedRNA followed by cDNA second strand synthe-
sis using random primers. Captured double stranded DNA
was digested using DpnII. The fragments that remained at-
tached to the beads were ligated to Illumina’s GEX DpnII
adapter 1 followed by digestion with MmeI resulting in the
release of tags. The tags were ligated using Illumina’s GEX
Adapter 2, amplified by PCR (15 cycles), and purified on
a polyacrylamide gel. Libraries were validated using a 2100
Bioanalyzer (Agilent), denatured using 0.1 M NaOH, di-
luted to 8 pM, and sequenced (single reads 36 nt, Illumina
Genome Analyzer) at MGX facility following the manu-
facturer’s instructions. Image analysis and base calling were
performed using the Illumina pipeline version 1.3.
A tag library was made from a UCSC refFlat table of
transcripts (refFlat.txt.gz; 15 January 2012) using an in-
house Perl script available upon request. The 16-nucleotide
sequences 3′ of all DpnII sites in every transcript were ex-
tracted. Unique tags that matched only one transcriptomic
location were kept and annotated as canonic when the cor-
responding DpnII site was the last 3′ site on the cDNA,
or transcriptomic when the corresponding DpnII site was
not the last 3′ site. GeneIDs were retrieved from the NCBI
(gene2refseq.gz; 19 January 2012).
Reads passing Illumina purity filters were kept for further
analysis. After trimming the adapter sequences, the 16nt-
and 17nt-trimmed reads were aligned to the DpnII-tag li-
brary without mismatch; counts for canonic and transcrip-
tomic tags corresponding to the same GeneID were pooled
using an in-house Perl script. Genes whose sum of tags in
the four libraries was <10 were filtered out. Raw counts
were normalized using the TMM (Trimmed Mean of M
values) method (19) as implemented in the edgeR package.
edgeR was used to identify differentially expressed genes
with a generalized linear model likelihood ratio test using
a paired design and a FDR set at 0.05 (20). DGE data from
this study have been submitted to the NCBI GEO database
under accession number GSE75942.
RNA-seq
The RNA-seq data regarding proliferation/quiescence/dif
ferentiation of the 3T3-L1 preadipocyte cell line have been
described previously (4) and are available at the NCBI
GEO web site under accession number GSE50612. To-
tal RNA was prepared 16 hours after Min6 cell transfec-
tion as above. Strand-specific libraries were prepared us-
ing Illumina’s TruSeq StrandedmRNASample Preparation
kit from four independent replicates of Plagl1- and NLS-
eGFP-transfected Min6 cells and sequenced on a HiSeq
2500 (single reads 50 nt) as described (4). Image analy-
sis and base calling were performed using the HiSeq Con-
trol Software and Real-Time Analysis component. Demul-
tiplexing was performed using Illumina’s Conversion Soft-
ware (bcl2fastq 2.17). The quality of the data was assessed
using FastQC v0.11.5 from the Babraham Institute and the
Sequence Analysis Viewer (Illumina). Potential contami-
nants were monitored with the FastQ Screen software from
the Babraham Institute.
We aligned RNA-seq reads to the mouse genome (UCSC
mm9) with the splice junction mapper TopHat 2.1.1, which
used Bowtie 2.2.8. We downloaded gene model annotations
from the UCSC database (genes.gtf 15 January 2012) and
GeneIDs from theNCBI (gene2refseq.gz, 19 January 2012).
Final read alignments having more than 3 mismatches were
discarded. We performed gene counting using the union
mode of HTSeq-count 0.6.1p1. Before statistical analysis,
genes with less than 20 reads (cumulating the eight ana-
lyzed samples) were filtered out. Counts were normalized
using the Relative Log Expression (RLE) method as im-
plemented in edgeR (20), which was used to identify dif-
ferentially expressed genes with a generalized linear model
likelihood ratio test using a paired design. We corrected P-
values for multiple testing using the Benjamini-Hochberg
FDRmethod. Genes with adjusted P-value <0.01 were de-
clared ‘differentially expressed’. RNA-seq data from this
study have been submitted to the NCBI GEO under ac-
cession number GSE84914. We analyzed the transcriptome
of two independent MEF preparations from Plagl1+/-pat.
and control littermate E13.5 embryos. MEF RNA-seq li-
braries were prepared and sequenced as above. Data were
processed as above with the following changes: bcl2fastq
2.18, Bowtie2 2.2.9, genes with <10 reads were filtered out.
Data have been submitted to the NCBI GEO under acces-
sion number GSE99409.
RT-qPCR
Total RNAs from cell lines and tissues were prepared us-
ing RNA NOW, treated with DNase I (DNA-free, Thermo
Fisher Scientific), and reverse-transcribed with MoMuL-
VRT (Thermo Fisher Scientific) according to the manufac-
turer’s instructions. To quantify the expression of Plagl1 tar-
get genes, we designed and validated primer pairs (Qiagen-
Operon, Supplementary Table S1) for real-time, quantita-
tive PCR, which was performed with ABI Prism 7000 and
the SybrGreen PCR Master Mix (Thermo Fisher Scien-
tific). Primers used to quantify Plagl1 expression quantified
all imprinted isoforms. We used geNorm (21) to select the
most appropriate housekeeping genes for each experiment.
The level of expression of each gene X was normalized to
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the geometric mean of the levels of expression of the se-
lected housekeeping genes, e.g. R1, R2 andR3, according to
the formula X/geometric mean (R1, R2, R3) = 2−(Cp(X)
– arithmetic mean(Cp(R1), Cp(R2), Cp(R3))), where Cp is
the threshold cycle. We normalized data with B2m in the
comparison between transfected Neuro-2a cells and em-
bryonic and neonate mouse tissues (Supplementary Figure
S4), Mrpl32 in muscle regeneration experiments (Figure 2,
Supplementary Figure S3), Tbp, Gus and Gapdh in in vitro
corticogenesis experiments (Figure 2, Supplementary Fig-
ure S3), Tbp, Gus andMrpl32 in MEF proliferation exper-
iments (Figure 1) and in the comparison of Neuro-2a and
Min6 cells (Figure 4).
ChIP-seq
Sixteen hours after transfection, we fixed Neuro-2a cells us-
ing 4% paraformaldehyde in PBS.We performed ChIP with
an anti-Zac1 antibody (5) using the protocol described by
A. Kouskouti and I. Kyrmizi (http://www.epigenome-noe.
net/researchtools/protocol.php protid=10.html). We used
two biological replicates with input chromatins as controls.
We prepared libraries according to Illumina’s instructions
using the ChIP-seq DNA sample prep kit (Cat. No. IP-102-
1001). For each sample, 10 ng of DNAwas repaired, result-
ing in blunt end fragments and adenylated on its 3′ ends.
Illumina’s adapters were ligated onto adenylated DNA. We
sized the DNA fragments using an agarose gel (fragment
size including adapters, 200 bp) followed by PCR (18 cy-
cles) to amplify fragments with both adapters. We validated
libraries on a 2100 Bioanalyzer (Agilent) and sequenced
them (single reads 36 nt) using Illumina Genome Analyzer
following the manufacturer’s instructions. We performed
image analysis, base calling and alignment to the mouse
genome (mm9) using the Illumina pipeline version 1.3. Re-
dundant reads that mapped at the exact same location were
reduced to a single count. We called peaks using the two
sample analysis method of Cisgenome v.1.2 (22) with in-
put chromatin as control and a 0.001 FDR. Preliminary
analysis of the two replicate experiments demonstrated a
good overlap of the lists of peaks. The number of peaks was
higher in one experiment but 75% of the peaks identified
in the experiment which produced the lower peak number
were also found in the replicate experiment. We performed
further analysis on pooled reads from input and immuno-
precipitated chromatins. Fifty one false-positive peaks lo-
cated in amplified regions of the input genome were re-
moved of the set of called peaks using Sole-Search (23). The
remaining 4638 peaks were annotated with the three clos-
est neighboring genes at a maximal distance of 20 kb using
CisGenome. Enriched sequence patterns in Plagl1 binding
regions were determined using Gibbs Motif Sampler pro-
vided by CisGenome that allowed calculating the Relative
Enrichment Levels for these motifs. We assessed the abun-
dance of the consensus motives in Plagl1 binding sites us-
ing the Motif Enrichment Analysis Framework (24). Rep-
resentative illustrations were made using IGB (Integrated
Genome Browser). ChIP-seq data from this study have been
submitted to the NCBI GEO database under the accession
number GSE75943.
ChIP-seq data for Nptx1 and Mpl promoters were
confirmed by ChIP-qPCR using primers listed in Sup-
plementary Table S1. Data were normalized using three
loci L1, L2, L3, devoid of Plagl1 binding sites accord-
ing to the formula: X/geometric mean (L1, L2, L3)
= 2(Ct(X)-arithmetic mean (Ct(L1), Ct(L2), Ct(L3)), where Ct is the
threshold cycle. Fold enrichments in anti-Plagl1 immuno-
precipitated chromatin were calculated over input chro-
matin used as control (16).
Data contextualization
Functional annotation of gene lists with GO terms and
KEGG pathways was performed with the Database for An-
notation, Visualization and Integrated Discovery (DAVID
6.8;May 2016) tools (25) using the expressed genes as back-
ground list.
RESULTS
Plagl1 is induced during cell cycle exit
We first sought to identify the physiological context
in which Plagl1 anti-proliferative activity was involved.
Zac1/Plagl1 was originally isolated in a functional screen
that also resulted in the isolation of a cDNA clone encod-
ing p53 (5). Plagl1 and Trp53 encode structurally unrelated
proteins but display similar functional properties as both
induce cell cycle arrest and apoptosis upon transfection in
different cell lines. Trp53 is best known for its physiologi-
cal role in the cell cycle arrest and eventually apoptosis that
DNA damage evokes. We thus tested whether the same ex-
perimental setting may also involve Plagl1. We irradiated
AtT20 pituitary cells with UV light to induce DNA dam-
age.We performedwestern blotting to detect p53 and Plagl1
at different time points after UV irradiation (Supplemen-
tary Figure S1). We observed the expected p53 induction
3 and 7 hours after UV irradiation. In contrast, Plagl1 was
not induced at any time point. We concluded that, although
Plagl1 and p53 share similar biological activities, these are
used in different biological contexts.
We surveyed Plagl1 expression during physiological cell
cycle arrest in various in vitro and in vivo models. Using
real-time PCR, we monitored Plagl1 expression in primary
mouse embryonic fibroblasts (MEFs) induced to quiescence
following confluence and contact inhibition at ∼7 days in
vitro (Figure 1A). We observed Plagl1 induction upon cell
cycle exit, when the proliferation marker Pcna was down-
regulated. Plagl1 was further induced upon prolonged qui-
escence. We confirmed these observations at the protein
level as the two Plagl1 splice variants (5) were induced with
very similar kinetics (Figure 1B). Using immunocytochem-
istry we also confirmed that Plagl1 expression was induced
in the nucleus. (Supplementary Figure S2). We did not de-
tect Plagl1 transcript and protein in Plagl1+/-pat. MEFs, no
matter their proliferation status (Figure 1A, B and Sup-
plementary Figure S2). This confirmed that reactivation of
the methylated, silenced maternal allele was not involved
in Plagl1 induction during cell cycle exit. We showed that
Plagl1 was also induced upon serum withdrawal-induced
quiescence (Figure 1C).
We used a differentiation paradigm in which mouse em-
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Figure 1. Plagl1 is induced during cell cycle exit. (A)Plagl1+/+ (circles) and
Plagl1+/-pat. (triangles) mouse embryonic fibroblasts (MEFs) were grown
in vitro until confluence (∼7 days in vitro), and kept confluent for 8 addi-
tional days with daily medium renewal. Pcna (blue) and Plagl1 (red) levels
were quantified by quantitative RT-PCR. (B) Protein lysates were prepared
from the same samples and probed with anti-Plagl1 and anti-actin antis-
era. (C) Wild-type, exponentially growing MEFs were deprived from fetal
bovine serum for the indicated time period. Pcna (blue) and Plagl1 (red)
expression levels were quantified as in A. One representative experiment of
three independent experiments is shown in each panel. For real-time PCR
experiments, data are mean ± S.D. of three independent reverse transcrip-
tion reactions quantified in triplicate.
bryonic stem (ES) cells were induced to cortical neurons
and glial cells in vitro (Figure 2A). This model was previ-
ously shown to recapitulate the major milestones of cortical
development, including the generation of a diverse reper-
toire of cortical pyramidal neurons in a timely ordered fash-
Figure 2. Plagl1 is induced during neurogenic (A), myogenic (B) and adi-
pogenic differentiation (C). (A) Embryonic stem cells (ESCs) were grown
in vitro and induced to cortical neural cells for the indicated period of time
as in (18). ESCs initially lost their pluripotency and generated neural pro-
genitors over the 12 first days. Neural progenitors progressively generated
the different cortical neuron subtypes and ultimately glial cells; the expres-
sion pattern of proliferation, pluripotency and corticogenesis markers is
displayed on Supplementary Figure S3A. Pcna (blue) and Plagl1 (red) ex-
pression levels were quantified by quantitative RT-PCR. Data are mean ±
S.E.M. of three independent experiments reversed transcribed in duplicate
and quantified in triplicate. (B) The tibialis anterior muscle of adult mice
was injected with notexin, a snake venom toxin that is directly toxic to
skeletal muscle. Satellite cells resumed proliferation, generated myoblasts
at day 1–2 that exited cell cycle at day 3–4, and differentiated into ma-
ture myocytes over the following 10 days; the expression pattern of pro-
liferation, inflammation, and myogenic markers is displayed on Supple-
mentary Figure S3B. We collected muscles at different time points during
muscle regeneration and quantified Pcna and Plagl1 expression by quan-
titative RT-PCR. Data are mean ± S.E.M. from one experiment on two
animals per time point reverse transcribed in duplicate and quantified in
octuplicate (Pcna) or quadruplicate (Plagl1). (C) Proliferating (P) 3T3-L1
preadipocytes were grown until confluence and remained quiescent (Q) for
2 days. Following addition of the adipogenic cocktail IDX (insulin, dex-
amethasone and IBMX), the cells resumed proliferation and entered the
so-called clonal expansion (CE) phase. The cells exited the cell cycle and
underwent adipogenic differentiation (D).NormalizedRNAseq counts for
proliferation markers (blue; Pcna, Dhfr, Mcm6, Prim1 and Mki67), adi-
pogenic differentiation markers (green; Cebpg, Pparg, Lpl, Cebpa, Plin1,
Adipoq, Lep) and Plagl1 (red) were displayed as a heat map.
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ion (18). Upon induction of corticogenesis, we confirmed
the down-regulation of stem cell markers and the induc-
tion of cortical markers (Supplementary Figure S3A). We
observed Plagl1 induction during the main period of neu-
ral progenitor cell cycle exit and differentiation into corti-
cal neural cells (Figure 2A). We also monitored Plagl1 ex-
pression in vivo during muscle regeneration induced by in-
jection of notexin, a snake venom toxin that kills myocytes
and induces the proliferation and differentiation of satel-
lite cells representing the muscle stem cell population (Fig-
ure 2B). We verified the transient expression of prolifera-
tion and inflammation markers and the progressive expres-
sion of myogenic factors until the restoration of myocyte
markers (Supplementary Figure S3B). We observed Plagl1
induction when proliferating myoblasts exited the cell cy-
cle to enter myogenic differentiation (Figure 2B). Finally,
we studied an in vitro adipogenesis model in which a pre-
adipocyte cell line was induced to adipogenic differentia-
tion by addition of the IDX hormonal cocktail (26). Cells
proliferated (Figure 2C, P) until they reached confluence
and entered quiescence (Figure 2C, Q). Two days later, we
added IDX; the cells resumed proliferation in the so-called
clonal expansion phase (Figure 2C, CE), definitively exited
the cell cycle 2–3 days later, and gradually differentiated into
lipid-accumulating adipocytes (Figure 2C, D). We quanti-
fied gene expression using RNA-seq and draw a heat map
with normalized gene counts for markers of proliferation
(Pcna, Dhfr, Mcm6, Prim1, Mki67), early (Cebpg, Pparg)
and late (Lpl, Cebpa, Plin1, Adipoq, Lep) adipogenic dif-
ferentiation, and for Plagl1. We noticed that Plagl1 expres-
sion was maximal when cells were either quiescent or dif-
ferentiated, i.e. they were not proliferating. All in all, these
data showed that Plagl1 was up-regulated under physiolog-
ical conditions when cells exited the cell cycle and entered
quiescence or differentiated.
Identification of Plagl1-regulated genes
To gain insights into Plagl1 mechanism of action, we de-
termined Plagl1 target genes using genome-wide transcrip-
tomics. Constitutively Plagl1-deficient cells may adapt to
loss of Plagl1 function by activating compensating regu-
latory mechanisms. We thus favored a cellular system in
which we experimentally induced Plagl1 expression in a
time-controlled fashion to focus on Plagl1 direct targets.
We selected the Neuro-2a neuroblastoma cell line, which
did not display detectable Plagl1 levels (data not shown).
Neuroblastoma are tumors derived from sympathetic neu-
roblasts, which express Plagl1 in vivo (27), indicating loss
of Plagl1 expression upon transformation (28). To avoid
non-specific effects due to over-expression, we transfected
Plagl1 at levels comparable to those observed in several tis-
sues in vivo (Supplementary Figure S4A). Plagl1 mRNA
levels in transfected Neuro-2a was 9.5 times higher than en-
dogenous Plagl1 expression in whole P1 sympathetic gan-
glia (Supplementary Figure S4A). Immunohistochemistry
using tyrosine hydroxylase (Th) and Plagl1 antibodies re-
vealed that only a small subset of neural cells expressed
Plagl1 in the superior cervical sympathetic ganglion (Sup-
plementary Figure S4B). This indicated that Plagl1 expres-
sion levels in transfected Neuro-2a cells were comparable to
that of Plagl1-positive sympathetic neural cells. We verified
thatPlagl1 displayed an anti-proliferative activity inNeuro-
2a cells by measuring the distribution of transfected cells in
the different phases of the cell cycle (Supplementary Fig-
ure S4C, D). Plagl1 transfection resulted in a G0/G1 arrest
and a concomitant decrease of the number of cells in the S
and G2/M phases. In contrast to previous observations in
other cellular systems (5), we did not find evidence of apop-
tosis following Plagl1 transfection in Neuro-2a cells (data
not shown).
We transfected proliferating Neuro-2a cells with chlo-
ramphenicol acetyltransferase (CAT) as a control orPlagl1.
We performed digital gene expression (DGE) profiling of
2 independent transfection experiments, and identified 351
DEgenes (Table 1, SupplementaryTable S2).We found only
three genes significantly repressed by Plagl1 transfection,
i.e. Rbm15 (x0.6),Hspa8 (x0.7) and Rps29 (x0.8). We tested
the differential expression of 59 genes by quantitative RT-
PCR (Supplementary Table S3), and 54 (92%) were con-
firmed as DE. To identify the biological processes that were
regulated by Plagl1 in Neuro-2a cells, we performed enrich-
ment analysis of GO terms and KEGG pathways (Supple-
mentary Table S4). We grouped the terms from the three
GO categories and KEGG pathways according to their se-
mantic similarities (Figure 3). As expected for a putative
tumor suppressor gene with proven anti-proliferative activ-
ity, we observed the enrichment of terms such as ‘regula-
tion of cell proliferation’, ‘pathways in cancer’ and ‘basal
cell carcinoma’. The most remarkable feature was the en-
richment of genes encoding ECM proteins, genes involved
in ECM-activated signaling, including cytoskeleton bind-
ing, and genes controlling cell adhesion and movement. We
also noted the over-representation of terms linked to signal-
ing, in particular cell–cell signaling, growth factor activity,
PDGF signaling, steroid hormone receptor activity, recep-
tor tyrosine kinase activity, and ion channels. The absence
of enrichment of terms related to cell cycle control, despite
Plagl1-induced cell cycle arrest (Supplementary Figure S4),
was noteworthy.
To test whether the genes regulated by Plagl1 in neurob-
lastoma cells were specific to this cell type, we transfected
Min6 insulinoma cells with plasmids encoding eGFP or
Plagl1. We performed RNA-seq analysis of the two trans-
fected populations and identified 441 DE genes (Supple-
mentary Table S5), including eight down-regulated.We per-
formed GO terms and KEGG pathways enrichment anal-
ysis (Supplementary Table S6) as previously described, and
identified terms very close to those associated with Plagl1-
regulated genes in Neuro-2a cells (Supplementary Figure
S5). Common enriched terms included ‘pathways in can-
cer’, ‘basal cell carcinoma’, terms related to ECM and
ECM-activated signaling, cell/focal adhesion as well as
terms related to other signaling pathways, e.g. Wnt, Hedge-
hog, adenylate cyclase, calcium etc. We found a large over-
lap between the genes regulated by Plagl1 in Neuro-2a and
Min6 cells; 133 genes were regulated in the 2 cell lines, 218
specifically in Neuro-2a cells and 308 specifically in Min6
cells (Supplementary Figure S6).
The genes called ‘differentially expressed’ (DE) in Neuro-
2a cells included 15 IGN genes, 5 of which were imprinted
and 2 additional IGs (Begain, Dio3). Twenty-one IGN
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Figure 3. GO terms and KEGG pathways enrichment analysis. Genes regulated by Plagl1 transfection into Neuro-2a cells were analyzed using the DAVID
bioinformatics resources (25). The figure displays the fold-enrichment of each statistically significant GO term/KEGG pathway. Circle color maps the GO
term/KEGGpathway category. Circle size maps the number of genes in eachGO term/KEGGpathway. The colored square next to eachGO term/KEGG
pathwaymaps the Benjamin–Hochberg-correctedP-value. The different GO terms/KEGGpathways were grouped according to their semantic similarities.
Table 1. Enrichment analysis of different categories of genes among Plagl1-regulated genes and genes with at least one Plagl1 binding site in Neuro-2a
neuroblastoma cells
DGE ChIP-seq





Genes with a Plagl1
binding site
All UCSC genes (23
100) P-value
Plagl1-regulated genes 351 217 351 1 × 10−81
Genes with a Plagl1 binding site 217 3082 5.4 × 10−53 3859
Imprinted Genes 7 61 0.001 25 115 0.03
ECM genes 17 177 5.3 × 10−6 92 369 1 × 10−5
IGN members (4) 15 297 0.009 88 407 0.002
PLAG1 target genes (36) 10 41 9.8 × 10−8 24 57 4 × 10−6
Plagl2 target genes (37) 8 20 2.6 × 10−8 17 23 2 × 10−9
Plagl1 target genes (38) 4 85 ns 19 108 ns
Neuroblastoma signature genes (40) 2 54 ns 16 59 0.02
IGN, PLAG1-, Plagl2-, Plagl1-target genes and the human neuroblastoma signature genes are from the indicated references. P-values were calculated using the hypergeometric
distribution. ns, not significant.
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Figure 4. Validation of the DGE and RNA-seq data by quantitative RT-PCR. (A) Imprinted and IGN genes called ‘differentially expressed’ in Plagl1-
transfected Neuro-2a or Min6 cells were quantified by qRT-PCR in CAT- or Plagl1-transfected transfected Neuro-2a cells. (B) Same as in A with GFP- or
Plagl1-transfected Min6 cells. Paternally and maternally imprinted genes are labeled in blue and red, respectively. Bi-allelically expressed genes are labeled
in black. Data are mean ± S.D. of four independent transfection experiments quantified in triplicate. The statistical significance of the difference between
control and Plagl1-transfected cells was tested using the Mann–Whitney U test. ***P < 0.001, **P < 0.01; *P < 0.05.
members were called DE in Min6 cells, including five IGs.
Three IGN members, including the imprinted Axl gene,
were called DE in both cell lines (Supplementary Figure
S6). To confirm these findings, we assessed the expression
levels of the 35 genes in control versus Plagl1-transfected
Neuro-2a and Min6 cells using RT-qPCR (Figure 4). RT-
qPCR confirmed the differential expression of all imprinted
and IGN genes called DE in both Neuro-2a andMin6 cells.
Four IGs and four IGN genes called DE in Min6 cells only
were found differentially expressed in Neuro-2a cells using
RT-qPCR.
Identification of Plagl1 binding sites
We performed ChIP-seq analysis of Plagl1-transfected
Neuro-2a cells. Using a 0.001 FDR, we identified 4689
peaks in Plagl1 ChIP samples compared to the input chro-
matin; 51 peaks were located in amplified regions of the in-
put genome and discarded from further analyses (Supple-
mentary Table S7).We performedChIP data quality control
(Supplementary Table S8) according to the guidelines pub-
lished by the ENCODE consortium (29). The average width
of peaks was 125.9 ± 127.9 bp, indicating we identified
mostly point-source peaks. The total number of uniquely
mapped reads ranged from 4.8 to 6.5Macross the four sam-
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ples we analyzed (duplicate input and immuno-precipitated
chromatin preparations). This is less than the recommended
10 M uniquely mapped reads for ChIP samples consisting
mostly of point-source peaks.However, the fraction of reads
in peaks (FriPs), which is recommended to be >1%, was
3.2% and the cross-correlation of the number of reads as-
signed to the forward and reverse strands within peaks was
0.80 (Supplementary Figure S7, Supplementary Table S8).
Therefore, our data fulfilled the three criteria for ChIP data
quality assessment according to the ENCODE consortium.
We also noted the presence of peaks at theH19 3′ enhancer,
which we previously demonstrated to be bound and regu-
lated by Plagl1 (16).
We annotated the ChIP peaks using CisGenome (Supple-
mentary Table S9). A peak was annotated with a gene if it
was located within ±20 kb of the gene body, i.e. from 20 kb
upstream its most upstream transcription start site (TSS) to
20 kb downstream its most downstream transcription end
site (TES). This region included the whole gene body, its
proximal promoter(s) and a number of, but possibly not
all, enhancers/silencers. Each peak was annotated with a
maximum of three different genes. This strategy was a com-
promise to include as many potentially regulated genes as
possible, but it had some obvious limitations as exemplified
by the Igf2-H19 locus (see discussion). Of the 4638 peaks
identified, 3876 were annotated by 3859 distinct genes, of
which 3082 were expressed in Neuro-2a cells. This num-
ber was in vast excess compared to the number of Plagl1-
regulated genes (Supplementary Figure S8) indicating that
Plagl1 binding to a large number of loci did not result in the
regulation of gene expression in Neuro-2a cells. The ChIP
peaks were mostly located outside the gene body and in in-
trons (Supplementary Figure S9).We looked at the distance
between each peak and the TSS of the nearest gene and
noticed that peak location was biased towards the proxi-
mal promoter region (Figure 5A) as expected for a conven-
tional transcription factor. Plagl1 binding sites in Plagl1-
regulated genes were also mostly located in the proximal
promoter with a further peak enrichment from –2 kb to –
0.5 kb relative to TSS (Figure 5A).We confirmed the higher
Plagl1 binding site number in Plagl1-regulated genes when
we looked at the distribution of peak number per TSS for all
genes versus Plagl1-regulated genes; the vicinity of Plagl1-
regulated TSS comprised more peaks than the population
of TSS close to all peaks (Figure 5B).
Among the 351 genes regulated by Plagl1 in Neuro-2a
cells, 217 (∼62%) had at least one Plagl1 binding site at
<20 kb (Table 1, Supplementary Figure S8). We also com-
pared the list of genes bound or regulated by Plagl1 to
the genes of the IGN (Table 1, Supplementary Figure S8).
Plagl1 was binding close to 88 of the 407 IGN genes present
in the UCSC database (∼22%, P < 2 × 10−3, Fisher’s ex-
act test). Interestingly, among expressed genes, IGN genes
were significantly more frequently regulated by Plagl1 than
non-IGN genes (Supplementary Figure S8; 15/297 versus
336/12 564, P< 0.02, Chi-square test). To further illustrate
howPlagl1 bindingmay contribute to IG regulationwe pro-
vide maps of consensus and observed Plagl1 binding sites at
imprinted loci (Supplementary Figure S10). Interestingly,
Plagl1 bound in Neuro-2a 148 (48%) of the 308 genes regu-
lated in Min6 cells only (Supplementary Figure S6).
Figure 5. Identification of Plagl1 binding sites in Neuro-2a cells. (A)
Comparison of the localization of Plagl1 binding sites (peaks) in Plagl1-
regulated genes (red) versus all genes with at least one Plagl1 binding site
(blue). (B) Comparison of the distributions of the number of Plagl1 bind-
ing sites in Plagl1-regulated genes (red) versus all genes with at least one
Plagl1 binding site (blue). (C) Identification of a consensus Plagl1 binding
site inferred from the sequences of all Plagl1 binding genomic regions.
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Plagl1 consensus binding site
The genome-wide identification of Plagl1 binding regions
offered the opportunity to deduce a Plagl1 consensus bind-
ing site in vivo. Using the de novo motif discovery module
of CisGenome (22,30), we identified four GC-rich consen-
sus motives that were significantly enriched among Plagl1
binding sites (Figure 5C, Supplementary Table S10). The
two most statistically significant motives, nos. 4 and 9
on Figure 5C, were similar: G(g/a)GGC(c/a)C(a/t)G and
G(g/a)GGCC(a/t) (g/c), respectively. The third statistically
significantmotif, no. 2, also included a stretch ofG followed
by a stretch of C. These consensus binding sites are rem-
iniscent of the G4C4 motif we previously reported for the
human PLAGL1 orthologue using an in vitro selection pro-
tocol (7) and of the primary Plagl1 GGG(C/G) (G/C)CCC
motif determined by protein-binding microarray (31). The
fourth significant binding site, G4N2G4, is also reminiscent
of the second category of binding sites we identified in the
same report, i.e. G4N6G4 (7). We also identified the Tn mo-
tif ubiquitously found in motif discovery experiments using
ChIP-seq data (30) as well as other AT-rich motives that
were not statistically significant.
We then assessed whether these consensus motives con-
tributed to gene regulation by Plagl1. We used the Motif
Enrichment Analysis framework (24) to compare the abun-
dance of the consensus motives in 532 Plagl1 binding sites
located in the vicinity of Plagl1-regulated genes versus 4106
binding sites located outside of Plagl1-regulated genes. We
showed that the G4(c/a)C3 and the G4N2G4 motives were
significantly over-represented in Plagl1 binding sites close
to Plagl1-regulated genes (Supplementary Table S11).
Mpl and Nptx1 are direct Plagl1 targets
To confirm that some of the identified regulated genes were
direct Plagl1 targets, we tested Mpl and Nptx1 promoter
regulation by Plagl1 (Figure 6).Mpl was induced 1849-fold
by Plagl1, mostly because it was barely detectable in CAT-
transfected Neuro-2a. Mpl proximal promoter region dis-
played a ChIP-seq peak that was confirmed by ChIP-qPCR
(Figure 6A). We cloned two fragments of theMpl proximal
promoter into the pGL3 luciferase reporter plasmid, and
measured luciferase activity inCAT- andPlagl1-transfected
Neuro-2a (Figure 6B). Plagl1 induced luciferase activity
∼25–30-fold from both constructs, confirming its ability to
transactivate theMpl promoter. On the other hand, the reg-
ulation of theNptx1 gene was more complex.Nptx1was in-
duced ∼46-fold by Plagl1; in contrast toMpl, Plagl1 bind-
ing occurred in intron 2 rather than in the proximal pro-
moter (Figure 6C). We also noted the presence of ChIP-
seq peaks that were not statistically significant in the vicin-
ity of the Nptx1 promoter, as well as a G4C4 consensus
binding site. ChIP-qPCR data close to this consensus site
suggested that the promoter may indeed contain a weak
Plagl1 binding site (Figure 6C). We cloned 2 fragments of
theNptx1 promoter into pGL3 and measured luciferase ac-
tivity in CAT- and Plagl1-transfected Neuro-2a cells. We
observed a 3-fold transactivation of the shortest fragment
by Plagl1 (Figure 6D). The longer fragment displayed an
elevated basal promoter activity, probably due to the pres-
ence of sequence from the neighboring Gm11762 gene pro-
Figure 6. Plagl1 regulates the thrombopoietin receptor (Mpl) and neuronal
pentraxin 1 (Nptx1) genes by direct transactivation of their respective pro-
moters. (A) ChIP-seq and ChIP-qPCR data were mapped to the Mpl lo-
cus. ‘IP reads’ designate reads from the anti-Plagl1 immuno-precipitated
fraction. (B) Fragments of the SV40 early (SV40-E) or Mpl (Mpl 0.8 kb,
Mpl 1.8 kb) promoters were subcloned into the pGL3 reporter plasmid
encoding the Firefly Luciferase, and transfected into Neuro-2a cells. The
pRK7-Gal plasmid containing the -galactosidase cDNAunder the con-
trol of a CMV promoter was co-transfected. The luciferase activity was
normalized to the -galactosidase activity of transfected cells. Data are
displayed as ratio of the normalized luciferase activity in pGL3promoter-
to pGL3basic-transfected cells. Plagl1 (closed bars) inhibited SV40 early
promoter and stimulatedMpl promoter fragments compared to chloram-
phenicol acetyl transferase (CAT; open bars). (C) Same as A for theNptx1
locus. The presence of two G4C4 sites in the Nptx1 gene is indicated. (D)
Same as B for the Nptx1 locus. Data are mean ± S.D. of four independent
experiments. ***P < 0.001; **P < 0.01; *P < 0.05.
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moter, and a weak 1.7-fold induction by Plagl1 (Figure 6D).
These data confirmed that Plagl1 directly bound and reg-
ulated Mpl and Nptx1 promoters, possibly in combination
with other regulatory elements in the case of theNptx1 gene.
Impact of loss of Plagl1 function in mouse embryonic fibrob-
lasts
As we showed that Plagl1 is induced upon cell cycle exit
in MEFs (Figure 1), we tested whether Plagl1 inactivation
altered the gene regulation that occurs upon cell cycle exit.
We platedMEFs at low density and let them grow until they
reached confluence and entered quiescence (Supplementary
Figure S11A). We observed no significant difference in the
growth rate and saturation density in Plagl1+/-pat. versus
wild type MEFs (Supplementary Figure S11A), indicating
that Plagl1 inactivation was not sufficient to alter MEF
proliferation in vitro. We performed RNA-seq analysis at
different time points when MEFs were proliferating (2
days in vitro), confluent (8 days in vitro), and quiescent
(10 and 12 days in vitro) (Supplementary Figure S11B).
We observed a large number of DE genes when wild type
MEFs exited the cell cycle; of the 15 788 genes expressed,
8799 were differentially expressed (FDR<0.01) upon
confluence (2 versus 8 days in vitro, data not shown).
It was noteworthy that several IGs, including Plagl1,
and IGN members were significantly up-regulated upon
confluence. In contrast, Plagl1 inactivation had a limited
impact on the transcriptome at most time points (Table
2, Supplementary Table S12); 29 genes were called DE
between wild type and Plagl1+/-pat. MEFs at day 2, 32 at
day 8, 183 at day 10, and 9 at day 12 (Table 2). In contrast
to Plagl1-transfected Neuro-2a and Min6 cells in which
DE genes were mostly up-regulated, genes dysregulated
in Plagl1+/-pat. MEFs included 99 up-regulated genes, 139
down-regulated genes, and three genes that were oppositely
regulated at different time points. Of the 238 genes called
DE at one time point at least, nine were called DE in
transfected Neuro-2a or Min6 cells, 37 displayed a Plagl1
binding site in transfected Neuro-2a cells, 30 were part of
the IGN, and 10 were IGs. Remarkably, 9 of the 10 IGs
and 8 of the 9 genes called DE in Neuro-2a or Min6 were
down-regulated in Plagl1+/-pat. MEFs. To identify the bio-
logical processes most affected by loss of Plagl1 function,
we performed GO term enrichment analysis of the 238
DE genes (Supplementary Table S13). Over-represented
terms were related to the ECM; ‘extracellular region’
(GO:0005576), ‘extracellular space’ (GO:0005615), ‘extra-
cellular matrix’ (GO:0031012), ‘proteinaceous extracellular
matrix’ (GO:0005578), ‘collagen binding’ (GO:0005518),
‘fibronectin binding’ (GO:0001968), and ‘insulin-like
growth factor binding’ (GO:0005520). We noted that these
terms were among those enriched in Plagl1-transfected
Neuro-2a (Figure 3) and Min6 (Supplementary Figure S5).
DISCUSSION
We showed that Plagl1 was up-regulated when cells from
different lineages proceeded from a proliferative to a quies-
cent or differentiated state (Figure 1, Supplementary Fig-
ure S2, Figure 2). This cellular pattern of expression was
in line with Plagl1 pattern of expression in the whole ani-
mal; Plagl1 was most abundantly expressed during late em-
bryonic development and its expression decreased during
post-natal growth deceleration in multiple organs (32). The
induction of Plagl1 expression upon cell cycle exit was not
limited to the murine gene as we previously showed that the
human PLAGL1 gene was induced under similar circum-
stances, i.e. human keratinocyte differentiation (33). Fur-
thermore, the context in which Plagl1/PLAGL1 induction
occurred was similar to the one we recently observed for
other imprinted genes (4), confirming that Plagl1 belongs
to the IGN.
As anticipated from previous studies in other cell lines,
Plagl1 expression led to cell cycle arrest in Neuro-2a neu-
roblastoma cells (Supplementary Figure S4). On the other
hand, we did not observe apoptosis following Plagl1 trans-
fection in this cell line. Only one term linked to apopto-
sis, i.e. ‘positive regulation of apoptotic process’, was over-
represented among genes induced by Plagl1 in Neuro-2a
cells. Of the 14 Plagl1-regulated genes that composed this
GO category, only three were specific thereof: Sept4, Irf5
and Ctrb1. The 11 remaining genes were also part of other
over-represented GO categories such as ‘regulation of cell
proliferation’, ‘MAPK signaling pathway’ and other signal-
ing pathways. This suggested that the main effect of Plagl1
induction in Neuro-2a was indeed the control of prolifera-
tion rather than apoptosis. This was further confirmed by
the absence of terms related to apoptosis among Plagl1-
regulated genes in Min6 cells. Although Plagl1 induced cell
cycle arrest in Neuro-2a cells, we did not observe the regu-
lation of components of the core cell cycle machinery, e.g.
cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors,
pocket proteins, or E2F transcription factors. The only no-
table exception was the CDK inhibitor Cdkn1c/p57Kip2,
which was induced ∼18-fold, in agreement with our obser-
vations that Cdkn1c was down-regulated in liver (16) and
MEFs (this study) from Plagl1-deficient embryos. Interest-
ingly, Cdkn1c is itself imprinted and displays functional
properties not shared by other CDK inhibitors (34). This
suggested that the regulation of Cdkn1c likely contributed
to the cell cycle arrest induced by Plagl1, but may have ful-
filled additional functions. In addition toCdkn1c, other reg-
ulated genes likely contributed to the observed cell cycle
arrest. Over-represented GO terms and KEGG pathways
included several signaling pathways, which were shown to
affect proliferation, e.g. ‘receptor protein tyrosine kinase
activity’, ‘MAPK signaling pathway’, ‘growth factor activ-
ity’, ‘PDGF binding’. The most remarkable set of over-
represented GO terms were related to the ECM. These in-
cluded terms linked to ECM constituents (‘proteinaceous
extracellular matrix’, ‘fibrillary collagen’), ECM-activated
signaling (‘ECM-receptor interaction’, ‘collagen binding’,
‘focal adhesion’), and an ECM-mediated function (‘cell
adhesion’). They also included terms related to the actin
cytoskeleton, a major target of ECM-activated signaling:
‘actin binding’, ‘filamin binding’, ‘ankyrin binding’, ‘Rho
GEF activity’, ‘cell–cell signaling’ and ‘cell movement’. We
also examined the alteration of gene regulation induced
by Plagl1 inactivation in mouse embryonic fibroblasts in
vitro. We previously demonstrated that Plagl1 inactivation
had profound impact on embryonic growth (16); however,
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Table 2. Enrichment analysis of different categories of genes among genes differentially expressed in wild-type versus Plagl1+/-pat. mouse embryonic
fibroblasts. P-values were calculated using the hypergeometric distribution
Day 2 (proliferation) Day 8 (confluence) Day 10 (quiescence) Day 12 (quiescence)



























29 (19/10) 32 (6/26) 183 (117/66) 9 (3/6)
IGN members 5 383 6 × 10−4 8 387 6 × 10−7 20 390 2 × 10−8 3 384 1 × 10−3
Imprinted genes 0 101 - 2 106 2 × 10−2 7 107 2 × 10−4 2 108 1 × 10−3
Plagl1-regulated genes in
Neuro-2a cells
1 269 3 × 10−1 1 291 3 × 10−1 4 295 2 × 10−1 1 281 1 × 10−1
Genes with 1+ Plagl1
binding site in Neuro-2a
cells
5 3133 2 × 10−1 2 3234 3 × 10−2 31 3266 4 × 10−2 3 3266 2 × 10−1
Plagl1-regulated genes in
Min6 cells
0 329 - 0 351 - 4 358 2 × 10−1 0 360 8 × 10−1
Plagl1-deficient MEFs grown in vitro did not display a
significant alteration of the proliferation rate and satura-
tion density compared to wild type MEFs (Supplementary
Figure S11). In agreement with this observation, Plagl1
inactivation did not extensively modify the transcriptome
of proliferating, confluent, or quiescent MEFs (Table 2)
suggesting that MEFs grown in vitro adapted to loss of
Plagl1 function by activating compensatory mechanisms.
Still, we found nine genes dysregulated by Plagl1 inactiva-
tion inMEFs that were identified as Plagl1 targets inNeuro-
2a or Min6 cells. In addition, 37 dysregulated genes dis-
played a Plagl1 binding site in Neuro-2a cells, 30 were part
of the IGN and 10 were IGs. A significant proportion of
the genes regulated upon wild type MEF confluence were
annotated by GO terms related to ECM structural con-
stituents, ECM-activated signaling, and ECM-dependent
processes. Interestingly, over-represented GO terms associ-
ated to genes dysregulated in Plagl1-deficient MEFs were
all related to the ECM. We concluded that Plagl1-deficient
MEF adapted to loss of Plagl1 function but for a limited
number of Plagl1 targets, IGN members, and ECM genes.
Altogether, the data from gain and loss of function Plagl1
mutants suggested that Plagl1 was not a modulator of the
core cell cycle machinery; it rather impacted cell prolifera-
tion by modulating the composition of the ECM and the
subsequent ECM-activated signaling. Retrospectively, the
experimental setting we used to identifyPlagl1 function and
regulated genes may have been suboptimal; the rigid plastic
vessels used for standard cell culture provide cells with ad-
hesive cues that prevent the observation of the effects of the
modulation of ECM composition. Future work will evalu-
atePlagl1 functional properties in amore permissive setting
such as 3D culture systems.
Plagl1/PLAGL1 belongs to a family of three zinc fin-
ger transcription factors that share considerable homology
in their zinc finger regions. In contrast to the candidate
tumor suppressor ZAC1/PLAGL1, PLAG1 and PLAGL2
are proto-oncogenes that are not imprinted. Because we
showed that the zinc finger region is involved in DNA bind-
ing (35), we tested whether Plagl1, Plag1 and Plagl2 shared
some target genes. We showed a significant overlap between
Plagl1 target genes identified in this study and the published
PLAG1 (36) and Plagl2 (37) targets (Table 1). In contrast,
we found only four genes in Neuro-2a cells, and three in
Min6 cells, in common between our study and a previous
one by Barz et al. (38) aimed at identifying Plagl1 target
genes in the hippocampal cell line HW3–5 (Table 1). Al-
though the observed difference might be attributed to the
use of different cell lines, this is unlikely because we found
a significant overlap between Plagl1 target genes in the neu-
roblastomaNeuro-2a cell line and the unrelated insulinoma
Min6 cell line (Supplementary Figure S6). We also noted
that 48% of the 351 Plagl1-regulated genes we identified
in Neuro-2a cells were found in a recent study by Rraklli
et al. usingE14.5 cerebral cortices electroporated in vivo (39)
(Supplementary Figure S12). Altogether, these data con-
firmed that we identified bona fide Plagl1 target genes, some
of which were shared with othermembers of the Plagl1 fam-
ily of transcription factors. Given Plagl1/PLAGL1 func-
tional properties and chromosomal localization, we previ-
ously suggested that PLAGL1might be the tumor suppres-
sor gene on 6q24 (8). Interestingly, we noted that Plagl1
was binding close to a significant proportion of the 59-gene
prognostic signature that sub-stratifies high-risk neuroblas-
toma patients (40) (Table 1). PLAGL1 is itself a member of
this signature and our work suggested that it may indeed
regulate a subset of the neuroblastoma signature genes.
We designed this study to identify direct Plagl1 tar-
get genes. Sixty-two percent of Plagl1-regulated genes in
Neuro-2a cells displayed a Plagl1 binding site at ±20 kb of
the gene body (Table 1). This percentage was an underesti-
mate as the 20 kb arbitrary cut-off prevented us to identify
some direct Plagl1 target as exemplified by the Igf2 gene.
Igf2 and H19 are two neighboring, reciprocally imprinted
genes on murine distal chromosome 7. They share an im-
printing control region located in between the two genes as
well as two enhancers located ∼8 kb downstream of H19
and ∼80 kb downstream Igf2. We previously showed (16),
and confirmed in this study, that murine Plagl1 binds to
these enhancers and directly regulates both genes. PLAGL1
binding to IGF2/H19 enhancers is conserved in humans
(41). We have also shown here that Plagl1 bound and trans-
activated the promoters of two identified target genes,Mpl
andNptx1. This led us to conclude that at least ∼2/3 of the
regulated genes we identified in this study were direct Plagl1
targets.
The number of Plagl1 binding sites was in vast excess to
the number of Plagl1-regulated genes (Table 1, Supplemen-
tary Figure S8). This observation is not unusual inChIP-seq
experiments (42) and the number of Plagl1 binding sites we
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observed (4638) is average. ChIP-seq on MyoD in murine
skeletal muscle cells identified approximately 30 000–60
000 MyoD binding sites (43). Similarly, the hematopoi-
etic factor Gata1 was reported to have over 15 000 DNA
binding sites in a mouse erythroblast line (44). Paradoxi-
cally, the calcium-response factor CaRF, which displayed
176 binding sites in cortical neurons from newborn mice
(45), is rather exceptional. Plagl1 is comparable to tran-
scription factors such as Tal1, which displayed 2994 bind-
ing sites in primary erythroid cells (46), the pregnane re-
ceptor Nr1i2/PXR, which displayed 3812 binding sites in
mouse liver (47), or p53, which displayed 4785 binding sites
in MEFs (48). One proposed explanation for large-scale
genome-wide transcription factor binding is the presence of
‘non-functional’ binding sites that serve no biological pur-
pose (49). Other hypotheses include the absence of appro-
priate transcriptional co-activators in Neuro-2a cells that
may be expressed in other cells types. The Min6 data sup-
ported in part this hypothesis as 48% of the 308 Min6-
specific, Plagl1-regulated genes included a Plagl1 binding
site identified in Neuro-2a cells. Because we aimed at identi-
fying mostly direct Plagl1 targets, including those that were
transiently regulated, and because we wanted to restrict
Plagl1 over-expression as much as possible, we looked at
Plagl1-regulated genes early after Plagl1 induction. Some
of the transcriptionally unproductive Plagl1 binding sites
may therefore correspond to genes that will be regulated
at a later stage. This argument may also explain why we
identified very few genes repressed by Plagl1. We noted that
Plagl1-regulated genes harbored more Plagl1 binding sites
than genes annotating all Plagl1 binding sites (Figure 5B).
This was suggestive of a mechanism in which occupancy of
one Plagl1 binding site did not result in increased transcrip-
tion but served as a nucleation event that permitted subse-
quent Plagl1 binding to neighboring loci to be transcrip-
tionally productive. Models involving ‘pioneer’ transcrip-
tion factors and homotypic cooperativity have been pre-
viously proposed (50,51). The Plagl1-regulated genes were
generally enriched in Plagl1 binding sites compared to all
genes located at ±20 kb of a Plagl1 binding site (Figure
5B). Many of these binding sites were located around the
TSS of the nearest gene (Figure 5A). These sites most of-
ten comprised aGC-rich sequence (Figure 5C) in agreement
with our previous results from SELEX experiments (7) and
from electro-mobility shift assays using the H19 enhancer
sequence (16). We concluded that Plagl1 is a transcription
factor that binds most often a defined, G4C4-like sequence
close to gene TSS, and that multiple Plagl1 binding at the
same promoter resulted in transcriptional regulation.
We recently described the imprinted gene network, a set
of imprinted and non-imprinted co-expressed genes that is
involved in the control of the transition between prolifera-
tion and quiescence-differentiation (4). How exactly mem-
bers of the IGN are co-regulated is unknown. Imprinted
genes are mostly clustered at a few loci and share regula-
tory elements. Imprinting control regions (ICRs) are DNA
elements that are differentially methylated on the paternal
andmaternal chromosome and govern the expression of the
parental alleles of neighboring genes. We showed that co-
regulation of imprinted genes occurs without remodeling of
ICRmethylation (4) suggesting that the co-regulation of im-
printed genes does not involve their ICRs. Other shared reg-
ulatory elements include enhancers and silencers. We men-
tioned the enhancers downstream of H19 that regulate the
maternal H19 and paternal Igf2 alleles. This mechanism
was demonstrated only for this imprinted locus and cannot
be generalized to all imprinted loci. Some imprinted genes
and most non-imprinted genes that compose the IGN are
not clustered; therefore, shared cis-regulatory elements can-
not explain the co-expression of IGN genes. In the present
work, we showed that imprinted genes and IGN genes
were over-represented among Plagl1-regulated and Plagl1-
bound genes (Table 1). In particular, ∼22% of the IGN
genes were close to a Plagl1 binding site. As observed for
all expressed genes, Plagl1 binding resulted in gene regula-
tion for only a minority of IGN genes; interestingly, Plagl1
binding close to IGNgenes resultedmore frequently in gene
regulation than binding close to non-IGN genes. All in all,
our work identified the first transcription factor that con-
tributed to the co-regulation of a significant proportion of
the IGN genes, and gave further credit to the existence of
the IGN as a novel identified biological machinery.
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